<code id='10A1B28F5C'></code><style id='10A1B28F5C'></style>
    • <acronym id='10A1B28F5C'></acronym>
      <center id='10A1B28F5C'><center id='10A1B28F5C'><tfoot id='10A1B28F5C'></tfoot></center><abbr id='10A1B28F5C'><dir id='10A1B28F5C'><tfoot id='10A1B28F5C'></tfoot><noframes id='10A1B28F5C'>

    • <optgroup id='10A1B28F5C'><strike id='10A1B28F5C'><sup id='10A1B28F5C'></sup></strike><code id='10A1B28F5C'></code></optgroup>
        1. <b id='10A1B28F5C'><label id='10A1B28F5C'><select id='10A1B28F5C'><dt id='10A1B28F5C'><span id='10A1B28F5C'></span></dt></select></label></b><u id='10A1B28F5C'></u>
          <i id='10A1B28F5C'><strike id='10A1B28F5C'><tt id='10A1B28F5C'><pre id='10A1B28F5C'></pre></tt></strike></i>

          Home / hotspot / entertainment

          entertainment


          entertainment

          author:focus    Page View:64
          3d heart myocarditis
          Adobe

          A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

          The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

          advertisement

          In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In